Marine compounds in the treatment of Alzheimer’s disease

Abstract

Brain shrinkage and cell death occurs due to Alzheimer's disease, a degenerative neurologic illness. Memory loss, social and behavioral deterioration, and the inability to operate independently are all symptoms of Alzheimer's disease, which is the most frequent cause of dementia. The accumulation of beta amyloid plaque and neurofibrillary tangles are the hallmarks of alzheimer’s disease and conventional treatments only aim to soothe symptoms rather than treat or prevent disease. Presently, the scientific community is working together to find innovative natural compounds that are helpful against Alzheimer's disease and marine natural products have been demonstrated to be potential possibilities. Currently bryostatin-1, homotaurine, dictyostatin, docohexanoic acid, rifampicin, gracilins are being tested for alzheimer’s disease. More clinical trials need to be conducted for marine compounds to be used in alzheimer’s patient. Along with that combination therapy consisting of marine compounds have a prospect of displaying better activity that need to be tested.